Drugs / Fexagratinib
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05533788 | Sep 2020 → Apr 2021 | — | Abbisko Therapeutics Co, Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02546661 | Dec 2016 → Mar 2020 overdue | infiltrating bladder urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01213160 | Nov 2010 → Jun 2013 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00979134 | Oct 2009 → Feb 2014 | high grade malignant neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05086666 | Jun 2021 → Aug 2023 | urothelial carcinoma | Abbisko Therapeutics Co, Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT02824133 | Sep 2015 → Sep 2017 | malignant glioma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT01824901 | Jan → Jul 2014 | non-small cell lung carcinoma, squamous cell lung carcinoma | ECOG-ACRIN Cancer Research Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01791985 | Jul 2012 → Nov 2016 | breast cancer | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT01202591 | Dec 2010 → Sep 2014 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 28 trials · 2 missed | ||||||
| Phase 2 | NCT05775874 | Sep 2022 → Sep 2025 | urothelial carcinoma | Abbisko Therapeutics Co, Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT04439240 | May 2016 → Jun 2019 | plasma cell myeloma, refractory malignant neoplasm | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2027 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02664935 | May 2015 → Nov 2023 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02117167 | Apr 2014 → Dec 2018 | non-small cell lung carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT02299999 | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01795768 | Sep 2012 → Sep 2014 | breast cancer, esophageal cancer, gastric cancer, squamous cell lung carcinoma | Royal Marsden NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT01457846 | Nov 2011 → Aug 2013 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AstraZeneca | Terminated | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02965378 | Oct 2014 → Jan 2017 | squamous cell lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-08 | Abbisko Therapeutics Co, Ltd | Results Abbisko Therapeutics announces preliminary Phase II safety and efficacy results of Fexagratinib (ABSK091) in patients with urothelial carcinoma abbisko.com ↗
Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced today the preliminary Phase II efficacy and safety results of its investigational pan-FGFR inhibitor Fexagratinib (ABSK091) in patients with urothelial carcinoma harboring FGFR2 or FGFR3 alterations in China's mainland. |
| 2016-04-14 | AstraZeneca | Results AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗
AZD4547 and AZD5363 synergistically inhibit prostate cancer progression by modulating MAPK and AKT activation |
All press releases naming this drug 6 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fexagratinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465060 ↗ |
| Known as | ABSK091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05533788 ↗ |
| Known as | ADSK091 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3348846 ↗ |
| Known as | AZD4547 | “To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer” NCT01795768 ↗ |
| Known as | KB-74810 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3348846 ↗ |
| Action | Inhibit | “fibroblast growth factor receptor (FGFR) inhibitor” PMID 28070720 ↗ Jan 2017 |
| Modality | Small molecule | — CHEMBL3348846 ↗ |
| Route | Oral | “Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)” NCT00979134 ↗ |
| Target | FGFR1 | “AZD4547 is a drug which specifically "blocks" proteins called fibroblast growth factor receptors (FGFR1) that are involved in the processes that help cancer cells to grow.” NCT01791985 ↗ |